<DOC>
	<DOCNO>NCT02924324</DOCNO>
	<brief_summary>The purpose study identify whether addition numb medicine inject directly site bone marrow procedure reduce pain use opioid pain medication bone marrow procedure . The addition medicine , call ropivacaine , experimental part study . This first time ropivacaine directly inject bone marrow site MSKCC Pediatrics .</brief_summary>
	<brief_title>Local Injection Pain Medication Reduce Pain After Bone Marrow Procedures Pediatric Neuroblastoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Ropivacaine</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Diagnosis neuroblastoma define International Neuroblastoma Risk Group Staging System ( INRGSS ) 22 3 18 year age Patient prior bone marrow procedure English speak History allergy investigational agent : ropivacaine amino amide analgesic History allergy standard agent : propofol Chronic daily opioid requirement Lansky/Karnofsky Score &lt; 60 Inability comply protocol requirement include refusal forego preprocedural opioid use Patient receive additional potentially painful intervention ( e.g . central line insertion/removal ) concurrent bone marrow procedure</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>local Injection</keyword>
	<keyword>pain Medication</keyword>
	<keyword>propofol</keyword>
	<keyword>ropivacaine</keyword>
	<keyword>16-1417</keyword>
</DOC>